Calumet
CLMT

Calumet (CLMT) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
UBSMaintainedNeutral$47.00 from $26.00Aug 25, 2026
Goldman SachsMaintainedNeutral$45.00 from $40.00Aug 18, 2026
TD CowenMaintainedHold$40.00 from $34.00Aug 12, 2026
Goldman SachsMaintainedNeutral$40.00 from $36.00Jul 30, 2026
HC Wainwright & Co.MaintainedBuy$60.00 from $33.00Mar 30, 2026
Goldman SachsMaintainedBuy$34.00 from $24.00Mar 12, 2026
Goldman SachsMaintainedBuy$24.00 from $20.00Jan 30, 2026
HC Wainwright & Co.MaintainedBuy$33.00Nov 10, 2025
Goldman SachsMaintainedBuy$20.00 from $15.00Oct 22, 2025
UBSMaintainedNeutral$13.25 from $12.00Aug 12, 2025
Wells FargoMaintainedOverweight$21.00 from $23.00May 14, 2025
B of A SecuritiesInitiated CoverageBuy$15.00May 13, 2025
Goldman SachsMaintainedBuy$14.00 from $16.00Apr 30, 2025
Wells FargoMaintainedOverweight$23.00 from $28.00Apr 9, 2025
UBSUpgradedSell → Neutral$12.00 from $15.00Mar 17, 2025
Wells FargoMaintainedOverweight$28.00 from $29.00Mar 5, 2025
HC Wainwright & Co.MaintainedBuy$33.00Mar 3, 2025
HC Wainwright & Co.MaintainedBuy$33.00Feb 12, 2025
UBSDowngradedNeutral → Sell$15.00 from $20.50Feb 4, 2025
HC Wainwright & Co.MaintainedBuy$33.00 from $25.00Jan 13, 2025

Frequently asked questions

  • What is the latest analyst rating on CLMT?

    On Aug 25, 2026, UBS maintained Calumet at Neutral with a price target of $47.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.